Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Failure in suppressing epilepsy; steps away from seizure-freedom Epilepsy, a central nervous system disorder that hinders the normal functioning of the brain, and leads to abnormality and loss of awareness. It affects over 70 million people worldwide, wherein nearly a quarter of patients with seizures have drug-...
Find More
Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly co...
Find More
World Epilepsy Day This World EPILEPSY Day fight to #endepilepsy. Educate people about epilepsy and raise awareness. #AimForZero. Turn purple for #purpleday.
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
